MacroGenics Inc. (MGNX)
2.29
-0.17 (-6.91%)
At close: Mar 03, 2025, 3:59 PM
2.28
-0.22%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 2.25 |
| Market Cap | 143.41M |
| Revenue (ttm) | 141.37M |
| Net Income (ttm) | -97.65M |
| EPS (ttm) | -1.57 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -1.17 |
| Analyst | Hold |
| Ask | 2.42 |
| Volume | 277,052 |
| Avg. Volume (20D) | 595,844 |
| Open | 2.46 |
| Previous Close | 2.46 |
| Day's Range | 2.27 - 2.50 |
| 52-Week Range | 2.27 - 21.88 |
| Beta | 2.01 |
About MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2013
Employees 339
Stock Exchange NASDAQ
Ticker Symbol MGNX
Website https://www.macrogenics.com
Analyst Forecast
According to 10 analyst ratings, the average rating for MGNX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 118.82% from the latest price.
Buy 20.00%
Hold 80.00%
Sell 0.00%
Next Earnings Release
MacroGenics Inc. is scheduled to release its earnings on Mar 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+1.89%
MacroGenics shares are trading higher after the co...
Unlock content with
Pro Subscription
5 months ago
+6.15%
MacroGenics shares are trading higher after the company announced it is set to present Phase 2 results from its TAMARACK trial on innovative cancer treatment at ESMO 2024.
